NCT02626312 2026-04-16
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
98 trialsNCT04785534 2026-04-15
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05666271 2026-04-13
Radiofrequency Ablation for Hepatocellular Carcinoma Using Octopus MP Electrodes
Seoul National University Hospital
Active not recruiting
NCT07444905 2026-04-13
Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma
Tongji Hospital
Active not recruiting
NCT04180072 2026-04-09
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
National Health Research Institutes, Taiwan
Phase NA Active not recruiting
NCT03186898 2026-04-03
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT03680508 2026-04-02
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
University of Hawaii
Phase 2 Active not recruiting
NCT05622136 2026-03-27
STRAT-aHCC
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT07493070 2026-03-25
Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca
Fujian Medical University Union Hospital
Phase NA Active not recruiting
NCT05128032 2026-03-19
PEDIR
Massachusetts General Hospital
Phase NA Active not recruiting
NCT03028311 2026-03-10
Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06859840 2026-03-10
LEAF
Zhejiang University
Phase NA Active not recruiting
NCT05103631 2026-03-06
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
Phase 1 Active not recruiting
NCT06018857 2026-03-06
Registry 17-009: Multi-Institutional Study Examining Patients With HCC Undergoing Liver Transplantation
The Cleveland Clinic
Active not recruiting
NCT04563338 2026-03-05
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
University Health Network, Toronto
Phase 2 Active not recruiting
NCT04721132 2026-03-05
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07437859 2026-02-27
Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor Microenvironment
Peking Union Medical College Hospital
Active not recruiting
NCT03519997 2026-02-11
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT05267080 2026-02-06
RESPECT
Cardiovascular and Interventional Radiological Society of Europe
Active not recruiting
NCT02967848 2026-02-05
LiverINSPECT
Royal North Shore Hospital
Active not recruiting
NCT04459273 2026-02-05
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT07380633 2026-02-02
Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial
Sun Yat-sen University
Phase 2 Active not recruiting
NCT01918683 2026-01-29
TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients
Abramson Cancer Center at Penn Medicine
Phase NA Active not recruiting
NCT05113186 2026-01-29
LENVABLA
Assistance Publique - Hôpitaux de Paris
Phase 2 Active not recruiting
NCT02432963 2026-01-28
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04550481 2026-01-21
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
Northwestern University
Phase 2 Active not recruiting
NCT05198609 2026-01-21
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Sun Yat-sen University
Phase 3 Active not recruiting
NCT06635694 2026-01-14
VIGILANT
Imperial College London
Active not recruiting
NCT05075993 2025-12-26
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02156739 2025-12-22
Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT06218511 2025-12-22
A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)
National Cancer Institute, Naples
Phase 1 Active not recruiting
NCT04658147 2025-12-18
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT06579833 2025-12-16
Histotripsy (HistoSonics®) for Liver Tumours
The University of Hong Kong
Phase NA Active not recruiting
NCT07278102 2025-12-11
KURE-YTT-HCC
Seoul National University Hospital
Active not recruiting
NCT03257761 2025-12-05
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
Phase 1 Active not recruiting
NCT03432806 2025-12-02
A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT03896646 2025-11-21
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT07230080 2025-11-17
Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer
Nanfang Hospital, Southern Medical University
Active not recruiting
NCT02293954 2025-11-14
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT04857684 2025-10-01
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
Massachusetts General Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT04687969 2025-09-25
Multimodal Machine Learning Characterization of Solid Tumors
Massachusetts General Hospital
Active not recruiting
NCT04605731 2025-09-10
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05194293 2025-09-04
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT07138885 2025-08-24
DRIVE-II
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05613621 2025-08-15
T4222
National Health Research Institutes, Taiwan
Active not recruiting
NCT05038254 2025-08-12
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05057013 2025-08-11
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
Phase 1/2 Active not recruiting
NCT05095519 2025-07-16
HepaSMART
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT06248528 2025-07-16
Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.
Tongji Hospital
Phase NA Active not recruiting
NCT07065786 2025-07-15
A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy
Zhongda Hospital
Active not recruiting